Menu
Search
|

Menu

Close
X

Kala Pharmaceuticals Inc KALA.OQ (NASDAQ Stock Exchange Global Select Market)

6.62 USD
+0.01 (+0.15%)
As of Nov 16
chart
Previous Close 6.61
Open 6.58
Volume 39,461
3m Avg Volume 90,308
Today’s High 6.81
Today’s Low 6.42
52 Week High 22.02
52 Week Low 6.15
Shares Outstanding (mil) 24.23
Market Capitalization (mil) 547.77
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.40 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.690
FY17
-3.061
FY16
-1.425
FY15
-0.412
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
--
5.69
Price to Book (MRQ)
vs sector
--
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
88.50
15.71
LT Debt to Equity (MRQ)
vs sector
68.25
11.53
Return on Investment (TTM)
vs sector
--
15.05
Return on Equity (TTM)
vs sector
--
16.62

EXECUTIVE LEADERSHIP

Mark Iwicki
Chairman of the Board, President, Chief Executive Officer, Since 2017
Salary: $500,588.00
Bonus: $387,450.00
Mary Reumuth
Chief Financial Officer, Treasurer, Since 2017
Salary: --
Bonus: --
Todd Bazemore
Chief Operating Officer, Since 2017
Salary: $46,731.00
Bonus: $190,000.00
Hongming Chen
Chief Scientific Officer, Since 2014
Salary: $322,086.00
Bonus: $129,944.00
Eric Trachtenberg
General Counsel, Corporate Secretary, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

100 Beaver St Ste 201
WALTHAM   MA   02453-8425

Phone: +1781.9965252
Site: kalarx.com/

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company’s product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient's eye, often at monthly intervals.

SPONSORED STORIES